IDH2 and astrocytoma (excluding glioblastoma): Recently, homozygous deletion of the cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) locus was added as grading criterium for CNS WHO grade 4 IDH-mutant astrocytomas [4, 8, 13]